Please try another search
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases. Its main drug candidate is Sibnayal, which has completed phase III clinical trial for the treatment of distal renal tubular acidosis, as well as cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or condition-causing anxiety unacceptable distress; and Levidcen, a galenic form of levetiracetam for the treatment of epileptic seizures. Advicenne S.A. was incorporated in 2007 and is headquartered in Paris, France.
Name | Age | Since | Title |
---|---|---|---|
Philippe Boucheron | - | 2022 | Chairman of the Board |
Catherine Dunand | 61 | - | Director |
Charlotte E. Sibley | 76 | 2018 | Independent Director |
Detlef Bockenhauer | - | 2019 | Member of Scientific Advisory Board |
Elena Levtchenko | - | - | Member of Scientific Advisory Board |
Larry Greenbaum | - | - | Member of Scientific Advisory Board |
Gema Ariceta | - | - | Member of Scientific Advisory Board |
Thibaut Roulon | 46 | 2011 | Director |
Bertrand Knebelmann | - | - | Member of Scientific Advisory Board |
André Ulmann | 73 | 2020 | Chief Medical Officer & Non-Voting Director |
Didier Laurens | 57 | 2021 | CEO, MD, General Director & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review